Alvotech (ALVO)
4.89
+0.03
(+0.62%)
USD |
NASDAQ |
Nov 09, 09:31
Alvotech Debt to Equity Ratio : -7.582 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.582 |
| March 31, 2026 | -5.162 |
| December 31, 2025 | -5.094 |
| September 30, 2025 | -7.254 |
| June 30, 2025 | -7.316 |
| March 31, 2025 | -4.059 |
| December 31, 2024 | -2.884 |
| September 30, 2024 | -3.435 |
| June 30, 2024 | -1.961 |
| March 31, 2024 | -1.670 |
| December 31, 2023 | -1.153 |
| September 30, 2023 | -1.536 |
| Date | Value |
|---|---|
| June 30, 2023 | -1.889 |
| March 31, 2023 | -1.274 |
| December 31, 2022 | -1.426 |
| September 30, 2022 | -2.297 |
| March 31, 2022 | 0.0005 |
| December 31, 2021 | 0.0005 |
| September 30, 2021 | 0.0005 |
| June 30, 2021 | 0.0005 |
| March 31, 2021 | 0.0005 |
| December 31, 2020 | 0.0005 |
| September 30, 2020 | 0.0005 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Agenus, Inc. | -2.633 |
| Amgen, Inc. | 3.763 |
| Regeneron Pharmaceuticals, Inc. | 0.0808 |
| Anika Therapeutics, Inc. | 0.1901 |
| BioCryst Pharmaceuticals, Inc. | -2.084 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.587B |
| Total Liabilities (Quarterly) | 1.779B |
| Shareholders Equity (Quarterly) | -191.48M |
| Current Ratio | 1.646 |
| Net Debt Paydown Yield | -3.42% |